Oramed Pharmaceuticals (ORMP) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Oramed Pharmaceuticals (ORMP) is Neutral.

The composite score behind that read is +0.13, weighing +0.36 of bullish evidence against -0.32 bearish.

Oramed Pharmaceuticals last closed at $4.33, +3.10% on the session.

Against the IVW growth benchmark the position is +2.30% over the forecast window.

The read is built from 15 underlying insights — 8 bullish and 7 bearish.

Agreement across those insights is 47%.

Oramed Pharmaceuticals has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Oramed Pharmaceuticals in the 99th percentile on valuation and the 94th percentile on return on equity, where 100 is best.

Oramed Pharmaceuticals is classified under Health Care / Pharmaceuticals, with a market capitalisation of $174.71M.

StockMap tracks Oramed Pharmaceuticals as the 93rd largest of the 151 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 90 Neutral, 46 Moderate Underperform and 15 Moderate Outperform.

On that composite Oramed Pharmaceuticals ranks 28th of 151 in the group, against a group median of -0.08.